PriceTargets.com logo

Addus HomeCare - ADUS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $131.63
  • Forecasted Upside: 8.79%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$120.99 As of 11/20/2024 01:00 AM ET
▲ +0.79 (0.66%)

This chart shows the closing price for ADUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Addus HomeCare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADUS

Analyst Price Target is $131.63
▲ +8.79% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Addus HomeCare in the last 3 months. The average price target is $131.63, with a high forecast of $150.00 and a low forecast of $83.00. The average price target represents a 8.79% upside from the last price of $120.99.

This chart shows the closing price for ADUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 contributing investment analysts is to moderate buy stock in Addus HomeCare. This rating has held steady since February 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$136.00 ➝ $136.00
11/6/2024StephensBoost TargetOverweight ➝ Overweight$143.00 ➝ $145.00
11/6/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$141.00 ➝ $136.00
11/4/2024MacquarieReiterated RatingOutperform ➝ Outperform$139.00 ➝ $139.00
10/11/2024MacquarieReiterated RatingOutperform ➝ Outperform$139.00 ➝ $139.00
10/11/2024KeyCorpInitiated CoverageOverweight$150.00
10/10/2024KeyCorpUpgradeStrong-Buy
9/23/2024OppenheimerBoost TargetOutperform ➝ Outperform$140.00 ➝ $145.00
9/3/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$141.00 ➝ $141.00
8/8/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$129.00 ➝ $141.00
8/8/2024TD CowenBoost TargetBuy ➝ Buy$128.00 ➝ $137.00
8/7/2024OppenheimerBoost TargetOutperform ➝ Outperform$130.00 ➝ $140.00
8/6/2024StephensReiterated RatingOverweight ➝ Overweight$138.00 ➝ $138.00
6/28/2024MacquarieInitiated CoverageOutperform$136.00
6/18/2024TD CowenBoost TargetBuy ➝ Buy$119.00 ➝ $128.00
6/7/2024OppenheimerBoost TargetOutperform ➝ Outperform$118.00 ➝ $130.00
5/31/2024StephensBoost TargetOverweight ➝ Overweight$120.00 ➝ $128.00
5/9/2024TD CowenBoost TargetBuy ➝ Buy$105.00 ➝ $119.00
5/7/2024StephensReiterated RatingOverweight ➝ Overweight$115.00
5/7/2024Bank of AmericaBoost TargetBuy ➝ Buy$115.00 ➝ $118.00
4/23/2024BarclaysDowngradeEqual Weight ➝ Underweight$83.00
3/26/2024OppenheimerReiterated RatingOutperform ➝ Outperform$118.00
3/6/2024BarclaysInitiated CoverageEqual Weight$88.00
2/29/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$102.00
2/5/2024William BlairReiterated RatingOutperform
1/17/2024OppenheimerReiterated RatingOutperform ➝ Outperform$118.00
12/12/2023TD CowenInitiated CoverageOutperform$105.00
11/1/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$109.00 ➝ $102.00
11/1/2023StephensLower TargetOverweight ➝ Overweight$110.00 ➝ $105.00
8/2/2023OppenheimerReiterated RatingOutperform ➝ Outperform$118.00
8/2/2023Raymond JamesBoost TargetOutperform ➝ Outperform$100.00 ➝ $105.00
8/2/2023StephensBoost TargetOverweight ➝ Overweight$100.00 ➝ $110.00
5/3/2023Royal Bank of CanadaLower Target$123.00 ➝ $109.00
5/3/2023OppenheimerLower Target$130.00 ➝ $118.00
4/5/2023StephensReiterated RatingOverweight$123.00
3/6/2023Royal Bank of CanadaBoost TargetOutperform$121.00 ➝ $123.00
11/2/2022Royal Bank of CanadaBoost TargetOutperform$110.00 ➝ $121.00
8/3/2022OppenheimerLower TargetOutperform$135.00 ➝ $130.00
8/3/2022Royal Bank of CanadaLower TargetOutperform$111.00 ➝ $110.00
6/28/2022Stifel NicolausInitiated CoverageBuy$101.00
6/21/2022StephensLower TargetOverweight$110.00 ➝ $101.00
5/4/2022Royal Bank of CanadaLower Target$125.00 ➝ $111.00
4/13/2022Bank of AmericaInitiated CoverageBuy$110.00
3/10/2022Royal Bank of CanadaBoost TargetOutperform$124.00 ➝ $125.00
11/3/2021Royal Bank of CanadaLower TargetOutperform$137.00 ➝ $124.00
8/4/2021Raymond JamesLower TargetOutperform$125.00 ➝ $115.00
10/1/2020OppenheimerReiterated RatingBuy
8/12/2020BMO Capital MarketsBoost Target$103.00 ➝ $115.00
8/11/2020OppenheimerBoost TargetOutperform$107.00 ➝ $115.00
6/17/2020Robert W. BairdBoost TargetOutperform$96.00 ➝ $100.00
6/1/2020SidotiBoost TargetBuy$96.00 ➝ $115.00
5/6/2020Robert W. BairdBoost TargetOutperform$80.00 ➝ $96.00
5/4/2020OppenheimerReiterated RatingBuy$107.00
4/20/2020Royal Bank of CanadaReiterated RatingBuy$98.00
3/18/2020SidotiLower TargetBuy$115.00 ➝ $96.00
12/10/2019OppenheimerBoost Target$96.00 ➝ $107.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 14 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 10 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 10 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 10 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 16 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 16 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 14 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 14 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Addus HomeCare logo
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.
Read More

Today's Range

Now: $120.99
Low: $119.57
High: $121.82

50 Day Range

MA: $128.52
Low: $118.27
High: $133.29

52 Week Range

Now: $120.99
Low: $85.43
High: $136.12

Volume

131,208 shs

Average Volume

131,569 shs

Market Capitalization

$2.19 billion

P/E Ratio

27.69

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Addus HomeCare?

The following equities research analysts have issued reports on Addus HomeCare in the last twelve months: Bank of America Co., Barclays PLC, KeyCorp, Macquarie, Oppenheimer Holdings Inc., Royal Bank of Canada, Stephens, StockNews.com, TD Cowen, TheStreet, and William Blair.
View the latest analyst ratings for ADUS.

What is the current price target for Addus HomeCare?

0 Wall Street analysts have set twelve-month price targets for Addus HomeCare in the last year. Their average twelve-month price target is $131.63, suggesting a possible upside of 8.8%. KeyCorp has the highest price target set, predicting ADUS will reach $150.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $83.00 for Addus HomeCare in the next year.
View the latest price targets for ADUS.

What is the current consensus analyst rating for Addus HomeCare?

Addus HomeCare currently has 1 sell rating, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ADUS.

What other companies compete with Addus HomeCare?

Other companies that are similar to Addus HomeCare include Amedisys, Hims & Hers Health, Guardant Health, Sotera Health and Option Care Health. Learn More about companies similar to Addus HomeCare.

How do I contact Addus HomeCare's investor relations team?

Addus HomeCare's physical mailing address is 6801 GAYLORD PARKWAY, FRISCO TX, 75034. The company's listed phone number is (469) 535-8200 and its investor relations email address is [email protected]. The official website for Addus HomeCare is www.addus.com. Learn More about contacing Addus HomeCare investor relations.